No Data
UPDATE 1-Biogen, Ionis to Discontinue Development of ALS Drug
Express News | Ionis And Biogen Say Development Of BIIB105 Will Be Discontinued Based On Data From Phase 1/2 Study
Express News | Biogen Inc: Development of Biib105, Will Be Discontinued Based on Data From Phase 1/2 Alspire Study
Express News | Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Express News | Ionis Pharmaceuticals Inc: Ion582 Was Safe and Well Tolerated at All Dose Levels
Express News | Ionis Pharmaceuticals Inc: Ion582 Demonstrated Consistent Improvements Across Multiple Functional Domains in Angelman Syndrome Patients